Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Zhe-yu Hu"'
Autor:
Zhe-Yu Hu, Binliang Liu, Ning Xie, Xiaohong Yang, Liping Liu, Huawu Xiao, Jing Li, Hui Wu, Jianxiang Gao, Jun Lu, Xuming Hu, Min Cao, Zhengrong Shui, Can Tian, Quchang Ouyang
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Aims This investigation aims to elucidate the treatment status of advanced HR+/HER2- breast cancer patients in Hunan Province of Central Southern China from November 2021 to December 2022. Methods Data from 301 patients with advanced HR+/HER
Externí odkaz:
https://doaj.org/article/e9c30214395a45e9b2c6da56ab5e2a2c
Autor:
Binliang Liu, Zhe‐Yu Hu, Ning Xie, Liping Liu, Jing Li, Xiaohong Yang, Huawu Xiao, Xuran Zhao, Can Tian, Hui Wu, Jun Lu, Jianxiang Gao, Xuming Hu, Min Cao, Zhengrong Shui, Yu Tang, Quchang Ouyang
Publikováno v:
Cancer Innovation, Vol 3, Iss 6, Pp n/a-n/a (2024)
Abstract Background CDK4/6 inhibitors (CDK4/6i) have shown promising results in the treatment of hormone receptor‐positive (HR+) metastatic breast cancer (MBC) when combined with endocrine therapy (ET). It is crucial to evaluate the actual effectiv
Externí odkaz:
https://doaj.org/article/13b880c7b9a24ee4801deeb38308ad66
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Case reportA 55-year-old male patient developed a mass in the left inguinal area with left lower limb swelling and first visited a local hospital 3 months earlier because of unrelieved pain. An MRI scan suggested left suprapubic branch and left aceta
Externí odkaz:
https://doaj.org/article/b18139dc9933423492cfcf2a50b7b5d3
Autor:
Zhe-Yu Hu, Min Yan, Huihua Xiong, Li Ran, Jincai Zhong, Ting Luo, Tao Sun, Ning Xie, Liping Liu, Xiaohong Yang, Huawu Xiao, Jing Li, Binliang Liu, Quchang Ouyang
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-10 (2023)
Abstract Background Human epidermal growth factor receptor 2 (HER2) targeted therapy combined with endocrine therapy has been recommended as an alternative treatment strategy for patients with hormone receptor (HR)-positive, HER2-positive metastatic
Externí odkaz:
https://doaj.org/article/945eca1f6a834632920aa7e7321a30fe
Autor:
Binliang Liu, Ning Xie, Can Tian, Ronghua Feng, Zhe-Yu Hu, Jing Li, Liping Liu, Huawu Xiao, Xiaohong Yang, Mengsi Zeng, Hui Wu, Jun Lu, Jianxiang Gao, Xuming Hu, Min Cao, Zhengrong Shui, Yu Tang, Tao Wu, Quchang Ouyang
Publikováno v:
Breast, Vol 72, Iss , Pp 103597- (2023)
Background: Inetetamab is a novel recombinant humanized anti-HER2 monoclonal antibody. This study aimed to evaluate the efficacy and safety of inetetamab and predictive factors for response in HER2-positive metastatic breast cancer (MBC) patients. Me
Externí odkaz:
https://doaj.org/article/59292865c1e34beda4acf59c61f9f89a
Publikováno v:
The Innovation, Vol 4, Iss 5, Pp 100494- (2023)
Externí odkaz:
https://doaj.org/article/2a6d194785d44ccc8244392a2f36f533
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
BackgroundAfter early-line (first- and second-line) endocrine therapy, hormone-receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancers (mBCs) become resistant to endocrine therapy. Genetic alterat
Externí odkaz:
https://doaj.org/article/46f06651406649088fe5451e53e68c93
Autor:
Zhe-Yu Hu, Yu Tang, Liping Liu, Ning Xie, Can Tian, Binliang Liu, Lixin Zou, Wei Zhou, Yikai Wang, Xuefeng Xia, Quchang Ouyang
Publikováno v:
EClinicalMedicine, Vol 51, Iss , Pp 101567- (2022)
Summary: Background: After multiple lines of therapies, no guideline or consensus is currently available for the treatment of patients with metastatic breast cancer. This study aims to evaluate the efficacy of a novel re-subtyping and treatment strat
Externí odkaz:
https://doaj.org/article/72bb24de6f034615a166185c412b8160
Autor:
Juan Wu, Hong-kai Su, Zhi-hui Yu, Shao-yan Xi, Cheng-cheng Guo, Zhe-yu Hu, Yue Qu, Hai-ping Cai, Yi-ying Zhao, Hua-fu Zhao, Fu-rong Chen, Yu-fan Huang, Shing-shun Tony To, Bing-hong Feng, Ke Sai, Zhong-ping Chen, Jing Wang
Publikováno v:
Cancer Cell International, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background Gliomas represent the largest class of primary central nervous system neoplasms, many subtypes of which exhibit poor prognoses. Surgery followed by radiotherapy and chemotherapy has been used as a standard strategy but yielded uns
Externí odkaz:
https://doaj.org/article/fe469c4dc56d47ef9c0c40a37126db74
Autor:
Liping Liu, Xiao Wang, Ying He, Wei Peng, Yu Tang, Ning Xie, Xiaobo Hu, Can Tian, Zhe-Yu Hu, Chongyu Hu, Xiangyan Liu, Huawu Xiao, Haoyu Zhou, Quchang Ouyang
Publikováno v:
BMJ Open, Vol 12, Iss 2 (2022)
Externí odkaz:
https://doaj.org/article/04a8d45cbb9b4bd1811ac461d5aa5194